Zicam, the cold remedy marketed by Matrixx Initiatives, is the subject of a warning letter from the Food and Drug Administration (FDA).
Several Zicam products have been associated with loss of sense of smell, or anosmia.
The warning advises that the product can no longer be marketed without FDA approval.